Assessment of the consistency and robustness of results from a multicenter trial of remission maintenance therapy for acute myeloid leukemia

Trials

Volumn 12, Issue , 2011, Pages

  Buyse, Marc ^a,b   Squifflet, Pierre ^a   Lucchesi, Kathryn J ^c   Brune, Mats L ^d   Castaigne, Sylvie ^e   Rowe, Jacob M ^f  

^a INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

^c MedVal Scientific Information Services   (United States)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e CENTRE HOSPITALIER DE VERSAILLES   (France)

^f TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; HAZARD RATIO; HUMAN; LEUKEMIA REMISSION; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; REMISSION; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; SURVIVAL; SURVIVAL RATE; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; HISTAMINE; HUMANS; INTERLEUKIN-2; LEUKEMIA, MYELOID, ACUTE; LINEAR MODELS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79953116798     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-12-86     Document Type: Article

References (20)

1. Harmonised Tripartite Guideline: Statistical Principles for Clinical Trials E9. , http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002928.pdf
2. Estey EH. Treatment of acute myeloid leukemia. Haematologica 2009, 94:10-16. 10.3324/haematol.2008.001263, 2625419, 19118375.
3. Redaelli A, Lee JM, Stephens JM, Pashos CL. Epidemiology and clinical burden of acute myeloid leukemia. Expert Rev Anticancer Ther 2003, 3:695-710. 10.1586/14737140.3.5.695, 14599092.
4. Burchill SA. What do, can and should we learn from models to evaluate potential anticancer agents?. Future Oncol 2006, 2:201-211. 10.2217/14796694.2.2.201, 16563089.
5. Maurillo L, Buccisano F, Del Principe MI, Del PG, Spagnoli A, Panetta P, Ammatuna E, Neri B, Ottaviani L, Sarlo C, Venditti D, Quaresima M, Cerretti R, Rizzo M, de FP, Lo CF, Arcese W, Amadori S, Venditti A. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 2008, 26:4944-4951. 10.1200/JCO.2007.15.9814, 18606980.
6. Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, Miller LL, Elfring GL, Pignon JP, Piedbois P. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007, 25:5218-5224. 10.1200/JCO.2007.11.8836, 18024867.
7. Buyse M, Burzykowski T, Michiels S, Carroll K. Individual- and trial-level surrogacy in colorectal cancer. Stat Methods Med Res 2008, 17:467-475. 10.1177/0962280207081864, 18285439.
8. Burzykowski T, Buyse M, Yothers G, Sakamoto J, Sargent D. Exploring and validating surrogate endpoints in colorectal cancer. Lifetime Data Anal 2008, 14:54-64. 10.1007/s10985-007-9079-4, 18205045.
9. Buyse ME, Squifflet P, Allard SE, Bhagwat D, Rowe JM. Leukemia-free survival (LFS) as a surrogate for overall survival (OS) in AML patients in remission: a trial of a novel immunotherapy with histamine dihydrochloride plus low-dose IL-2 (HDC/IL-2) [abstract]. Haematologica 2008, 93(Suppl 1):209-210.
10. Yothers G. Toward progression-free survival as a primary end point in advanced colorectal cancer. J Clin Oncol 2007, 25:5153-5154. 10.1200/JCO.2007.13.6796, 18024861.
11. Rowe JM. Optimal induction and post-remission therapy for AML in first remission. Hematology Am Soc Hematol Educ Program 2009, 396-405.
12. Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer 2006, 107:2099-2107. 10.1002/cncr.22233, 17019734.
13. Brune M, Castaigne S, Catalano J, Gehlsen K, Ho AD, Hofmann WK, Hogge DE, Nilsson B, Or R, Romero AI, Rowe JM, Simonsson B, Spearing R, Stadtmauer EA, Szer J, Wallhult E, Hellstrand K. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood 2006, 108:88-96. 10.1182/blood-2005-10-4073, 16556892.
14. Wallhult EA, Whisnant JK, Nilsson BI, Bhagwat D, Hellstrand K, Brune ML. Quality of life during remission maintenance immunotherapy in acute myeloid leukemia: a prospective assessment using EORTC QLQ-C30 in a randomized phase III trial of histamine dihydrochloride plus low-dose interleukin-2 [abstract]. Haematologica 2008, 93(Suppl 1):316.
15. Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 1991, 10:1665-1677. 10.1002/sim.4780101105, 1792461.
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560. 10.1136/bmj.327.7414.557, 192859, 12958120.
17. Marschner IC. Regional differences in multinational clinical trials: anticipating chance variation. Clin Trials 2010, 7:147-156. 10.1177/1740774510361974, 20338904.
18. Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 2000, 1:49-67. 10.1093/biostatistics/1.1.49, 12933525.
19. Burzykowski T, Molenberghs G, Buyse M. The Evaluation of Surrogate Endpoints 2005, New York, NY: Springer.
20. National Cancer Institute SEER Survival Data 1988-2005 (SEER 9). National Cancer Institute., http://seer.cancer.gov/faststats/selections.php?series=cancer